These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17280587)

  • 1. Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity.
    Bueno L; de Ponti F; Fried M; Kullak-Ublick GA; Kwiatek MA; Pohl D; Quigley EM; Tack J; Talley NJ
    Neurogastroenterol Motil; 2007 Jan; 19(1 Suppl):89-119. PubMed ID: 17280587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: drugs interfering with visceral sensitivity for the treatment of functional gastrointestinal disorders--the clinical evidence.
    Kuiken SD; Tytgat GN; Boeckxstaens GE
    Aliment Pharmacol Ther; 2005 Mar; 21(6):633-51. PubMed ID: 15771750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial overview: serotonergic agents in functional GI disorders: targeting the brain-gut axis.
    Wessinger S; Jones MP; Crowell MD
    Curr Opin Investig Drugs; 2005 Jul; 6(7):663-6. PubMed ID: 16044660
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of serotonin in gastrointestinal physiology and pathology.
    Cirillo C; Vanden Berghe P; Tack J
    Minerva Endocrinol; 2011 Dec; 36(4):311-24. PubMed ID: 22322654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin and its role in colonic function and in gastrointestinal disorders.
    Costedio MM; Hyman N; Mawe GM
    Dis Colon Rectum; 2007 Mar; 50(3):376-88. PubMed ID: 17195902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visceral hypersensitivity in functional disorders of the upper gastrointestinal tract.
    Sarnelli G; Vandenberghe J; Tack J
    Dig Liver Dis; 2004 Jun; 36(6):371-6. PubMed ID: 15248374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: The role of serotonergic agents in the treatment of patients with primary chronic constipation.
    Cash BD; Chey WD
    Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1047-60. PubMed ID: 16305718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs affecting visceral sensitivity: ready for the prime time?
    Delvaux MM; Gay G
    Dig Dis; 2006; 24(1-2):99-104. PubMed ID: 16699268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The serotonin signaling system: from basic understanding to drug development for functional GI disorders.
    Gershon MD; Tack J
    Gastroenterology; 2007 Jan; 132(1):397-414. PubMed ID: 17241888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing of visceral sensitivity.
    Mulak A
    J Physiol Pharmacol; 2003 Dec; 54 Suppl 4():55-72. PubMed ID: 15075449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-hydroxytryptamine and the gastrointestinal tract: where next?
    Sanger GJ
    Trends Pharmacol Sci; 2008 Sep; 29(9):465-71. PubMed ID: 19086255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin and the GI tract.
    Hasler WL
    Curr Gastroenterol Rep; 2009 Oct; 11(5):383-91. PubMed ID: 19765366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonergic modulation of visceral sensation: upper gastrointestinal tract.
    Tack J; Sarnelli G
    Gut; 2002 Jul; 51 Suppl 1(Suppl 1):i77-80. PubMed ID: 12077073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo and transgenic animal models used to study visceral hypersensitivity.
    Fioramonti J; Gebhart GF
    Neurogastroenterol Motil; 2007 Jan; 19(1 Suppl):20-8. PubMed ID: 17280583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonergic receptors in therapeutic approaches to gastrointestinal disorders.
    Neal KB; Bornstein JC
    Curr Opin Pharmacol; 2006 Dec; 6(6):547-52. PubMed ID: 16973419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of 5-hydroxytryptamine receptors on intestinal afferents in the regulation of visceral sensitivity.
    Greenwood-van Meerveld B
    Neurogastroenterol Motil; 2007 Aug; 19 Suppl 2():13-8. PubMed ID: 17620083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gastrointestinal motility disorders and drugs: opioids, calcium antagonists, nitrates, peptides, prostaglandins and 5-hydroxytryptaminergic drugs (part II)].
    Jovanović-Mićić D; Samardzić R; Beleslin B
    Srp Arh Celok Lek; 1994; 122(3-4):88-92. PubMed ID: 17972818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HT in the enteric nervous system: gut function and neuropharmacology.
    McLean PG; Borman RA; Lee K
    Trends Neurosci; 2007 Jan; 30(1):9-13. PubMed ID: 17126921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiological concepts of functional dyspepsia and irritable bowel syndrome future pharmacotherapy.
    Dobrek Ł; Thor PJ
    Acta Pol Pharm; 2009; 66(5):447-60. PubMed ID: 19894640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutic targets for enteric nervous system disorders.
    De Giorgio R; Barbara G; Furness JB; Tonini M
    Trends Pharmacol Sci; 2007 Sep; 28(9):473-81. PubMed ID: 17764756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.